CytomX Therapeutics, Inc. (CTMX) Current Ratio
- Current ratio · latest quarter: Value 9.36×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.36× | Current assets / current liabilities. $373.15M ÷ $39.86M ≈ 9.36× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 373.15M USD | Assets, Current |
| Current obligations | 39.86M USD | Liabilities, Current |
| Cash and equivalents | 17.22M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 313.06M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 37.49M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.94M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $373.15M | $39.86M | $17.22M | $313.06M | $37.49M | (m) | $1.94M | (m) | 9.36× |
| 2026-03-31 | $353.10M | $34.02M | $28.83M | $317.88M | $646.00K | (m) | $1.37M | (m) | 10.38× |
| 2025-12-31 | $143.92M | $46.62M | $12.67M | $124.39M | $2.01M | (m) | $1.30M | (m) | 3.09× |
| 2025-09-30 | $149.22M | $41.03M | $34.19M | $109.44M | $1.63M | (m) | $646.00K | (m) | 3.64× |
| 2025-06-30 | $164.62M | $39.22M | $49.04M | $109.05M | $1.87M | (m) | $227.00K | (m) | 4.20× |
| 2025-03-31 | $86.63M | $50.20M | $47.60M | $32.28M | $1.96M | (m) | $276.00K | (m) | 1.73× |
| 2024-12-31 | $107.31M | $85.77M | $38.05M | $62.57M | $3.10M | (m) | $1.09M | (m) | 1.25× |
| 2024-09-30 | $124.18M | $119.23M | $40.58M | $77.01M | $3.35M | (m) | $1.42M | (m) | 1.04× |
| 2024-06-30 | $143.08M | $142.86M | $43.25M | $93.94M | $2.77M | (m) | $611.00K | (m) | 1.00× |
| 2024-03-31 | $167.25M | $144.54M | $36.19M | $114.10M | $13.18M | (m) | $1.96M | (m) | 1.16× |
| 2023-12-31 | $182.94M | $155.91M | $17.17M | $157.34M | $3.43M | (m) | $1.46M | (m) | 1.17× |
| 2023-09-30 | $201.20M | $146.79M | $26.02M | $168.09M | $2.42M | (m) | $1.71M | (m) | 1.37× |
| 2023-06-30 | $187.80M | $141.38M | $57.54M | $123.32M | $1.90M | (m) | $1.03M | (m) | 1.33× |
| 2023-03-31 | $212.28M | $151.26M | $56.36M | $148.15M | $1.09M | (m) | $2.20M | (m) | 1.40× |
| 2022-12-31 | $237.10M | $152.61M | $193.65M | $0.00 | $35.99M | (m) | $2.81M | (m) | 1.55× |
| 2021-12-31 | $310.30M | $77.87M | $205.53M | $99.70M | $790.00K | (m) | $2.82M | (m) | 3.98× |
| 2020-12-31 | $324.01M | $68.11M | $191.86M | $124.26M | $798.00K | (m) | $3.00M | (m) | 4.76× |
| 2020-09-30 | $340.31M | $102.03M | $176.81M | $144.27M | $543.00K | (m) | $3.64M | (m) | 3.34× |
| 2020-06-30 | $366.57M | $98.78M | $291.39M | $55.01M | $206.00K | (m) | $4.93M | (m) | 3.71× |
| 2020-03-31 | $400.07M | $106.00M | $143.29M | $104.64M | $130.01M | (m) | $3.78M | (m) | 3.77× |
| 2019-12-31 | $303.33M | $85.59M | $188.43M | $107.72M | $13.00K | (m) | $4.16M | (m) | 3.54× |
| 2019-09-30 | $334.78M | $76.13M | $164.65M | $161.07M | $7.00K | (m) | $4.55M | (m) | 4.40× |
| 2019-06-30 | $366.68M | $78.67M | $149.39M | $199.75M | $10.00M | (m) | $4.52M | (m) | 4.66× |
| 2019-03-31 | $405.08M | $96.22M | $190.41M | $206.19M | $44.00K | (m) | $9.51M | (m) | 4.21× |
| 2018-12-31 | $445.48M | $97.91M | $247.58M | $188.55M | $97.00K | (m) | $5.13M | (m) | 4.55× |
| 2018-09-30 | $472.51M | $86.27M | $259.75M | $204.81M | $56.00K | (m) | $6.87M | (m) | 5.48× |
| 2018-06-30 | $366.67M | $83.21M | $132.91M | $202.24M | $25.14M | (m) | $4.24M | (m) | 4.41× |
| 2018-03-31 | $367.03M | $69.71M | $142.16M | $219.32M | $81.00K | (m) | $5.35M | (m) | 5.27× |
| 2017-12-31 | $388.60M | $61.15M | $177.55M | $196.56M | $10.14M | (m) | $4.21M | (m) | 6.36× |
| 2017-09-30 | $376.37M | $71.24M | $284.23M | $47.05M | $40.18M | (m) | $2.87M | (m) | 5.28× |
| 2017-06-30 | $340.68M | $60.63M | $272.86M | $63.06M | $158.00K | (m) | $6.36M | (m) | 5.62× |
| 2017-03-31 | $166.91M | $37.13M | $85.66M | $76.86M | $213.00K | (m) | $3.70M | (m) | 4.50× |
| 2016-12-31 | $188.15M | $35.77M | $104.64M | $77.29M | $2.16M | (m) | $6.60M | (m) | 5.26× |
| 2016-09-30 | $183.31M | $23.68M | $59.76M | $118.71M | $240.00K | (m) | $517.00K | (m) | 7.74× |
| 2016-06-30 | $199.61M | $22.22M | $62.38M | $133.42M | $285.00K | (m) | $1.43M | (m) | 8.98× |
| 2016-03-31 | $184.55M | $17.00M | $67.90M | $112.74M | $316.00K | (m) | $4.96M | (m) | 10.85× |
| 2015-12-31 | $189.75M | $15.74M | $59.82M | $126.89M | $372.00K | (m) | $4.70M | (m) | 12.06× |
| 2015-09-30 | $115.07M | $13.97M | $36.19M | (m) | $406.00K | (m) | $2.70M | (m) | 8.24× |
| 2014-12-31 | $66.85M | $11.16M | $64.40M | $0.00 | $1.88M | (m) | $1.92M | $1.42M | 5.99× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |